Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

Source: 
Endpoints
snippet: 

Less than a year ago, Third Rock startup Revolution Medicines shed its antifungal ambitions and remade itself as an oncology company. Now, the Redwood City-based biotech has apparently wooed Sanofi $SNY into a bang up deal on its first cancer program.